ArticleDrug design, development and therapy2017
Metal organic frameworks as a drug delivery system for flurbiprofen.
Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 136 citations in OpenAlex.
- Innovative Trinuclear Copper(I)-Based Metal-Organic Framework: Synthesis, Characterization, and Application in Laser-Induced Graphene Supercapacitors.Nanomaterials (Basel, Switzerland) · 2026Article
- d-Penicillamine-loaded MIL-100(Fe) for precise targeted copper chelation in Wilson's disease.RSC advances · 2026Article
- Magnetic Nanoparticles Combined With Pulsed Electromagnetic Field Alleviate Chondrocyte Necroptosis in Osteoarthritis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Quality by Design (QbD)-Based Development of a Self-Nanoemulsifying Drug Delivery System for the Ocular Delivery of Flurbiprofen.Pharmaceutics · 2025Article
- Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.Nanomedicine (London, England) · 2025Article
- Microwave-Responsive Metal-Organic Frameworks (MOFs) for Enhanced In Vitro Controlled Release of Doxorubicin.Nanomaterials (Basel, Switzerland) · 2024Article
- Review
- Current status and prospects of MIL-based MOF materials for biomedicine applications.RSC medicinal chemistry · 2023Review
- Recent Advances in Metal-Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release.Pharmaceutics · 2022Review
- Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy.Pharmaceutics · 2022Article
- Design and degradation of permanently porous vitamin C and zinc-based metal-organic framework.Communications chemistry · 2022Article
- Metal-based nano-delivery platform for treating bone disease and regeneration.Frontiers in chemistry · 2022Review
- Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Differentiation of Epoxide Enantiomers in the Confined Spaces of an Homochiral Cu(II) Metal-Organic Framework by Kinetic Resolution.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Synthesis of Ribose-Coated Copper-Based Metal-Organic Framework for Enhanced Antibacterial Potential of Chloramphenicol against Multi-Drug Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2021Article
- Enhanced Antibacterial Potential of Amoxicillin againstAntibiotics (Basel, Switzerland) · 2021Article
- Metal-Organic Frameworks-Based Nanomaterials for Drug Delivery.Materials (Basel, Switzerland) · 2021Article
- Metal-Organic Frameworks for Drug Delivery: A Design Perspective.ACS applied materials & interfaces · 2021Review
- Overview and Update on Methods for Cargo Loading into Extracellular Vesicles.Processes (Basel, Switzerland) · 2021Article
- Nanoscale Metal-Organic Frameworks and Their Nanomedicine Applications.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetal organic frameworks (MOFs) have attracted more attention in the last decade because of a suitable pore size, large surface area, and high pore volume. Developing biocompatible MOFs such as the MIL family as a drug delivery system is possible. PURPOSE: Flurbiprofen (FBP), a nonsteroidal anti-inflammatory agent, is practically insoluble in aqueous solution, and, therefore, needs suitable drug delivery systems. Different biocompatible MOFs such as Ca-MOF and Fe-MILs (53, 100, and 101) were synthesized and employed for FBP delivery. PATIENTS AND
methodsA sample of 50 mg of each MOF was mixed and stirred for 24 h with 10 mL of 5 mg FBP in acetonitrile (40%) in a sealed container. The supernatant of the mixture after centrifuging was analyzed by high-performance liquid chromatography to determine the loaded quantity of FBP on the MOF. The overnight-dried solid material after centrifuging the mixture was analyzed for loading percent using X-ray diffraction, Fourier-transform infrared spectroscopy, scanning electron microscopy, nuclear magnetic resonance, and FBP release profile.
resultsThe loading values of FBP were achieved at 10.0%±1%, 20%±0.8%, 37%±2.3%, and 46%±3.1% on Ca-MOF, Fe-MIL-53, Fe-MIL-101, and Fe-MIL-100, respectively. The FBP release profiles were investigated in a phosphate buffer solution at pH 7.4. The total release of the FBP after 2 days was obtained at 72.9, 75.2, 78.3, and 90.3% for Ca-MOF, Fe-MIL-100, Fe-MIL-53, and Fe-MIL-101, respectively.
conclusionThe MOFs are shown to be a promising drug delivery option for FBP with a significant loading percent and relatively prolonged drug release.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.